Cellectis S.A. filings document a foreign private issuer focused on clinical-stage gene-edited cell and gene therapies. Recent Form 6-K reports furnish press-release exhibits covering financial-results announcements, business updates, research presentations, and clinical program disclosures for the company's allogeneic CAR T and gene-editing platforms.
The filing record also reflects disclosure topics tied to Cellectis' Nasdaq and Euronext Growth listings, including its Form 20-F reporting status, pipeline updates for lasme-cel, eti-cel and cema-cel, license and collaboration references involving Servier, Allogene and AstraZeneca, and formal communications about strategy, research data and corporate developments.
Cellectis S.A. files its annual report on Form 20-F, outlining its gene-editing cell therapy business, capital structure and key risks. As of December 31, 2025, outstanding capital stock totaled 100,339,441 shares, including 72,339,441 ordinary shares and 28,000,000 convertible preferred shares.
The company remains a clinical-stage biopharmaceutical business focused on allogeneic CAR T-cell therapies and reports significant ongoing losses. For 2025, Cellectis recorded a net loss from continuing operations of $67.6 million, with research and development expenses of $93.5 million and an accumulated deficit of $334.1 million attributable to shareholders.
Liquidity is supported by cash and cash equivalents of $61.5 million and fixed-term deposits classified as current financial assets of $144.8 million as of December 31, 2025, which management believes will fund operations into the second half of 2027. The report emphasizes extensive risk factors around competition, funding needs, manufacturing complexity, regulatory approvals and dependence on partners and third parties.
Cellectis reported strong 2025 clinical progress but a wider annual loss. For the year ended December 31, 2025, total revenues and other income rose to $79.6 million from $49.2 million, mainly from its collaboration with AstraZeneca. Research and development and SG&A spending were broadly stable, yet a swing to a $34.9 million net financial loss from a $22.8 million gain drove the consolidated net loss attributable to shareholders to $67.6 million, or $0.67 per share, versus a $36.8 million loss, or $0.41 per share, in 2024.
Clinically, allogeneic CAR-T programs advanced. In r/r B-ALL, lasme-cel showed an 83% overall response rate at the recommended Phase 2 dose and 100% overall response rate in the target Phase 2 population, with all target patients becoming transplant-eligible. A pivotal Phase 2 BALLI-01 trial is ongoing, with first interim analysis expected in Q4 2026 and a BLA submission anticipated in 2028. In r/r NHL, eti-cel delivered an 88% overall response rate and 63% complete response rate at the current dose level, with a full Phase 1 dataset expected in Q4 2026.
Cash, cash equivalents and fixed-term deposits totaled $211 million as of December 31, 2025, which the company believes provides runway into H2 2027. Cellectis also highlighted progress on cssDNA non-viral templates, TALE base editor safety, and collaborations with AstraZeneca, Servier/Allogene and Iovance.
Cellectis S.A. filed a report stating it will release its fourth quarter and full year 2025 financial results on March 19, 2026, after the U.S. market close. An investor conference call and webcast will follow on March 20, 2026, at 8:00 AM ET / 1:00 PM CET to discuss the results and provide a business update.
Cellectis set out its 2026 strategy, centered on advancing its allogeneic CAR-T pipeline, key partnerships, and extending its cash runway. The company is executing a pivotal Phase 2 BALLI-01 trial of lasme-cel in relapsed/refractory B-ALL, targeting a first interim analysis for 40 patients in Q4 2026, after Phase 1 data showed a 68% overall response rate with Process 2, rising to 83% at the recommended Phase 2 dose and 100% in the target Phase 2 population, with strong MRD-negative complete remissions and a favorable safety profile.
For eti-cel in relapsed/refractory NHL, preliminary Phase 1 data from NATHALI-01 showed an 88% response rate and 63% complete remissions, with an IL-2 combination cohort starting enrollment in Q1 2026 and full Phase 1 data expected in Q4 2026. Cellectis highlighted progress under its AstraZeneca collaboration (up to 10 products), potential milestones and royalties from Servier/Allogene including up to $340 million tied to a CD19 program, and upcoming Iovance IOV-4001 data. The company believes its cash, cash equivalents, and fixed-term deposits will fund operations into H2 2027.
Cellectis S.A. has filed a Form 6-K to make its interim report for the nine-month period ended September 30, 2025 available to investors. The report is furnished as Exhibit 99.1.
This interim report is also incorporated by reference into Cellectis’ existing Form F-3 and Form S-8 registration statements, meaning those shelf and equity compensation registrations now include the updated nine-month 2025 information.